TELA Bio to Participate in Canaccord Genuity’s 41st Annual Growth Conference

MALVERN, Pa., Aug. 03, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the Company will participate in Canaccord Genuity’s 41^st Annual Growth Conference.

TELA Bio's management is scheduled to present at Canaccord Genuity’s 41^st Annual Growth Conference on Thursday, August 12, 2021 at 2:00 PM EDT. Interested parties can access the live and archived webcast at ir.telabio.com.

About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The Company is committed to providing patients with advanced, economically effective biologic material repair solutions to minimize long-term exposure to permanent synthetic materials and improve clinical outcomes. TELA Bio's OviTex® and OviTex PRS Reinforced Tissue Matrix products are purposefully designed to address the shortcomings of existing reinforcement materials in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. For more information, visit www.telabio.com.

Investor Contact
Greg Chodaczek
347-620-7010 
ir@telabio.com